Xeris Biopharma Holdings (XERS) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- —
- Estimate
- —
- Surprise
- -154.1%
- Revenue (period 2026-06-30)
- $92.1M
- Score at report (before → after)
- 6.4 → 6.4/10
Revenue source: xbrl.
How the report landed
TrendMatrix's engine moved from Hold (6.4/10) to Sell at 6.4/10 after the report.
Where TrendMatrix's rating stands now
TrendMatrix currently rates XERS Hold at 6.0/10.
0 of the last 4 quarters beat the estimate; this quarter's -154.1% surprise compares with a +338.5% four-quarter average. Next scheduled report: 2026-11-05.
What supports the rating
- Sector modifier (Healthcare): +0.5
- Strong growth profile
What argues against it
- Concentration risk — Supplier: Regis Technologies
- Concentration risk — Supplier: Lonza Tampa
- Analyst target reached - limited upside remaining
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $10.88
- Price target
- $11.19
- Stop
- $10.11
- Upside to target
- +2.9%
- Reward-to-risk
- 0.2:1
Model outputs from TrendMatrix’s engine as of 2026-10-29 — shown for context, not personalized investment advice.
XERS at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Drug Manufacturers - Specialty & Generic
- Market cap
- $1.94B
- P/E (fwd)
- 54.1
- 52-week range
- $5.25–$11.42
- Off 52-week high
- 4.8%
- RSI (14)
- 55
- Volume vs avg
- 0.14×
- Score today
- 6.0/10